Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation (IMAGE)
Caption
Figure 4. Incidence of primary and secondary outcomes (total original cohort). (A) Cardiovascular events. (B) Congestive heart failure. (C) Arteriosclerotic disease. (D) Cardiovascular death. The incidence of composite cardiovascular events, arteriosclerotic disease, congestive heart failure, and cardiovascular death within 5 years was significantly lower in the Xa-I group than in the non-Xa-I group. CI, confidence interval; HR, hazard ratio; Xa-I, Factor Xa inhibitor.
Credit
Copyright: © 2025 Takahashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content